Regulatory agency discretion among competing industries: inside the FDA MK Olson The Journal of Law, Economics, and Organization 11 (2), 379-405, 1995 | 138 | 1995 |
Are novel drugs more risky for patients than less novel drugs? MK Olson Journal of Health Economics 23 (6), 1135-1158, 2004 | 123 | 2004 |
Substitution in regulatory agencies: FDA enforcement alternatives M Olson The Journal of Law, Economics, and Organization 12 (2), 376-407, 1996 | 111 | 1996 |
Firm characteristics and the speed of FDA approval MK Olson Journal of Economics & Management Strategy 6 (1), 377-401, 1997 | 101 | 1997 |
The risk we bear: the effects of review speed and industry user fees on new drug safety MK Olson Journal of health economics 27 (2), 175-200, 2008 | 97 | 2008 |
Pharmaceutical policy change and the safety of new drugs MK Olson The Journal of Law and Economics 45 (S2), 615-642, 2002 | 85 | 2002 |
Agency rulemaking, political influences, regulation, and industry compliance MK Olson Journal of Law, Economics, and Organization 15 (3), 573-601, 1999 | 81 | 1999 |
Managing delegation in the FDA: reducing delay in new-drug review MK Olson Journal of Health Politics, Policy and Law 29 (3), 397-430, 2004 | 59 | 2004 |
Regulatory reform and bureaucratic responsiveness to firms: The impact of user fees in the FDA MK Olson Journal of Economics & Management Strategy 9 (3), 363-395, 2000 | 40 | 2000 |
Political influence and regulatory policy: the 1984 drug legislation MK Olson Economic Inquiry 32 (3), 363-382, 1994 | 22 | 1994 |
Explaining Reductions In FDA Drug Review Times: PDUFA Matters: There was little reduction in FDA review times until after the introduction of prescription drug user fees. MK Olson Health Affairs 22 (Suppl1), W4-S1-W4-S2, 2003 | 17 | 2003 |
Explaining regulatory behavior in the FDA: political control vs. agency discretion MK Olson Advances in the Study of Entrepreneurship, Innovation, and Growth 7, 71-108, 1996 | 17 | 1996 |
Examining firm responses to R&D policy: An analysis of pediatric exclusivity MK Olson, N Yin American Journal of Health Economics 4 (3), 321-357, 2018 | 16 | 2018 |
Eliminating the US drug lag: implications for drug safety MK Olson Journal of Risk and Uncertainty 47, 1-30, 2013 | 16 | 2013 |
How have user fees affected the FDA MK Olson Regulation 25, 20, 2002 | 16 | 2002 |
PDUFA and initial US drug launches MK Olson Mich. Telecomm. & Tech. L. Rev. 15, 393, 2008 | 12 | 2008 |
Political influence and the development of US regulatory policy: the 1984 drug legislation M Olson Center for Economic Policy Research, Stanford University, 1991 | 7 | 1991 |
Stanford Research Workshop on the Pharmaceutical Industry: Summary of Presentations and Lead-Off Discussants L Cabral, R Noll, M Olson, E Steinmueller CEPR Publication 206, 1990 | 7 | 1990 |
New clinical information and physician prescribing: How do pediatric labeling changes affect prescribing to children? MK Olson, N Yin Health Economics 30 (1), 144-164, 2021 | 4 | 2021 |
Which Factors Shape and Limit the Role of the Center for Drug Evaluation and Research’s Advisory Committees? S Schulman, MK Olson, RW Makuch Drug information journal: DIJ/Drug Information Association 36, 281-289, 2002 | 4 | 2002 |